rep4/TR::REP4 基因過度表現株之藥物敏感性結果

於圖十七發現，rep4/TR::REP4基因過度表現株 WJC44 與 WJC48 對於 azoles 類藥 物中之triazole – fluconazole、voriconazole、itraconazole 的藥物敏感性降低，變的比較具 有抵抗性(resistance)。和野生型 SC5314(REP4/REP4)相比，fluconazole 的 MIC 值由 0.75

~1.0 µg/ml 提高至 1.5 µg/ml；而 voriconazole 的 MIC 值由 0.016 µg/ml 提高至 0.023 µg/ml；而 itraconazole 的 MIC 值由 0.032 µg/ml 提高至 0.064 µg/ml。從 agar dilution assay 中發現(圖十八)，rep4/TR::REP4 基因過度表現株 WJC44 與 WJC48 對於 azoles 類藥物中 之imidazole- miconazole 的敏感性提高，變的比較敏感(sensitive)，是否因為 azoles 類藥 物之subtype 不同(triazole 或 imidazole)而造成不同的藥物敏感性現象，有待更近一步釐 清。由rep4/TR::REP4 基因過度表現株 WJC44 與 WJC48 對 imidazole- miconazole 的敏 感性提高，變的比較敏感(sensitive)可見 REP4 基因的功能的確與抗藥性有關。

破壞 REP4 基因時對於藥物敏感性沒有明顯的變異現象發生，但是過量表現 REP4 基因時會影響白色念珠菌的藥物敏感性，猜測可能的原因有：(1)過量表現的 Rep4p 除了 會與CDR1 作用外，可能還會和其他與藥物敏感性相關的基因作用，因而造成白色念珠 菌的抗藥性發生改變。(2)Rep4p 本身可能不是直接造成藥物敏感性改變的主要原因，而 是當Rep4p 與 CDR1 結合後，吸引了其他蛋白質靠近 CDR1，彼此間形成了一個蛋白質 複合物(protein complex)，進而影響了白色念珠菌的藥物敏感性變化。

5.9 REP4 基因不會影響白色念珠菌之型態轉換

於圖十九之結果指出，在誘導菌絲形成之狀況下(37 ºC 高溫培養及加入 10 %胎牛血 清)，不論是 rep4/rep4 同型缺陷突變株 WJC31 與 WJC42 或是 rep4/TR::REP4 基因過度 表現株WJC44 與 WJC48，皆不會影響芽管形成，也就是不會影響白色念珠菌之型態轉 變。故在此實驗條件下，REP4 基因和白色念珠菌之型態變化無關。

5.10 REP5基因不會影響白色念珠菌之型態轉換，且REP5基因過度表現株不會影響白色 念珠菌之藥物敏感性。

REP5基因位於白色念珠菌contig19-10215中，ORF號碼為19.4884。Rep5p具有785個 胺基酸，大小約86.35 kDa。經過序列比對分析後發現，REP5基因和啤酒酵母的ORF YEL007w具有相似性。YEL007w為具有666個胺基酸的蛋白質，於啤酒酵母中的功能未 知。Rep5p的6 ~ 792個胺基酸與YEL007w的3 ~ 660個胺基酸之間的相同性(identity)達27

%，相似性(similarity)達40 %(Evalue= 5e^-27)(圖二十五)。又REP5基因和YEL007w皆與 Schizosaccharomyces pombe中與gluconate transport induction有關的Gti1p具有微弱之相似 性(但N端前80幾個胺基酸相同性高達40 %以上，且此範圍內包含了一個可能的Pka1 phosphorylation site KRWTDG)(圖二十五)(Caspari, 1997)。先前研究發現，白色念珠菌的 a和α細胞必須先經過表型轉換(phenotypic switch)，從white階段轉變成opaque階段才有交 配(mating)能力(Miller & Johnson, 2002)。研究發現，在白色念珠菌中，REP5(YEL007w) 基因會在a和α細胞內表現，但不會在a/α細胞表現，故REP5(YEL007w)基因的表現會受 a1/α2調控(被抑制)(Tsong et al., 2003)。又，Micheal等人的研究發現，在HBR1/hbr1(HBR1 為白色念珠菌white-opaque轉換的抑制者)異型缺陷突變株內與MTLa1與MTLα1,2的缺陷 株內，REP5(YEL007w)基因的mRNA含量有提高現象(約提高2 ~ 3倍)(Pendrak et al., 2004)。先前研究得知，在啤酒酵母2B/int5314CDR1p-lacZ 中，REP5基因能夠提高 β-galactosidase 活性約7倍(紀錦昇，交大碩士論文，2004)。又，實驗發現REP5基因能夠 活化FLO11::lacZ的表現(Rottmann et al., 2003)，而Flo11p/Muc1p已知為啤酒酵母中和 pseudohyphal以及invasive growth有關的蛋白質(Lambrechts et al., 1996; Lo & Dranginis, 1998)。綜合上述結果，為了想知道REP5基因是否牽涉到抗藥性和型態(morphology)變 化，便開始著手研究REP5基因。

由於一直無法順利得到rep5/rep5同型缺陷突變株，故採用四環黴素調控系統 (Nakayama, et al., 2000)並在有無添加doxycycline的情況下，調控REP5基因的表現形式。

添加doxycycline時，REP5基因會受到抑制而不表現；不加doxycycline時，REP5基因會 過度表現。由於doxycycline會影響野生型SC5314生長狀況，使SC5314菌株生長受到抑 制，菌落變得較衰弱。為了避免結果難以判讀與解釋，故於之後的藥物敏感性實驗，都 不添加doxycycline(不觀察REP5基因抑制現象)，只觀察REP5基因過度表現之影響。由圖 二十二及二十三之結果得知，不論於藥物敏感性試驗(Etest)或是agar dilution assay中，在 不添加doxycycline的狀況下(REP5基因過度表現)和野生型SC5314(REP5/REP5)相比，

REP5基因過度表現株WJC58與WJC63，對於azoles類藥物- fluconazole、 ketoconazole、

itraconazole、voriconazole以及miconazole和polyenes類藥物-amphotericin B 的藥物敏感性 皆無顯著變化。而在型態研究方面得知，在誘導菌絲形成之狀況中(37 ºC高溫培養及加 入10 %胎牛血清)，加入doxycycline抑制REP5基因表現時，仍然會有芽管生成(圖二十 四)。綜合所有實驗結果發現：REP5基因不會影響白色念珠菌之型態轉換，且REP5基因 過度表現株WJC58與WJC63不會影響白色念珠菌之藥物敏感性。為了更清楚得知REP5 基因是否和藥物敏感性有關，我們必須再次利用同源重組置換方式完整破壞REP5基 因，希望能夠得到rep5/rep5同型缺陷突變株，以供近一步研究REP5基因和抗藥性之間的 關係。

六、未來展望

1. 已知rep3/rep3同型缺陷突變株對於azoles類藥物fluconazole、voriconazle和miconazole 的敏感性提高，變得較敏感。此現象可於rep3/rep3::REP3單套基因置入補救株中驗 證。由於本論文之agar dilution assay研究只有觀察菌株對於miconazole的敏感性現 象，故之後可以fluconazole及voriconazole進行agar dilution assay，觀察是否同樣具有 和藥物敏感性試驗(Etest)相同之結果。

2. 探討野生型SC5314(REP3/REP3)、rep3/rep3同型缺陷突變株與rep3/rep3::REP3單套 基因置入補救株中排藥幫浦CDR1 mRNA含量。如果REP3基因藉由直接和CDR1作用 而造成白色念珠菌之抗藥性生成，那麼我們應該可在rep3/rep3同型缺陷突變株內觀 察到CDR1 mRNA表現量下降，而於rep3/rep3::REP3單套基因置入補救株中，CDR1 mRNA表現量會回升。

3. 以四環黴素調控系統過量表現REP3基因，觀察REP3基因過量表現時的藥物敏感性 現象是否會與rep3/rep3同型缺陷突變株相反。

4. 再次利用同源重組置換實驗破壞REP4基因，並以所得到的rep4/rep4同型缺陷突變株 驗證藥物敏感性實驗(Etest)中的正確表型，之後可於實驗中觀察rep4/rep4同型缺陷 突變株、rep4/rep4::REP4單套基因置入補救株與rep4/TR::REP4基因過度表現株中的 排藥幫浦CDR1 mRNA表現量，藉此研究REP4基因和CDR1之間的作用。

5. 利用同源重組置換實驗完整破壞 REP5 基因，並以所得到的 rep5/rep5 同型缺陷突變 株進行藥物敏感性實驗(Etest)，試著找出 REP5 基因和 CDR1 之間的相關性。

七、參考文獻

Albertson GD, Niimi M, Cannon RD, Jenkinson HF. (1996). Multiple effluxmechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother.

40(12):2835-2841.

Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC. (2003). Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis. 22(4):

22(4):254-257.

Aravind L, Landsman D. (1998). AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res. 26(19):4413-21.

Bermam J, Sudbery PE. (2002). Candida Albicans: a molecular revolution built on lessons from budding yeast. Nat Rev Genet. 3(12):918-930. Review.

Bruno VM, Mitchell AP. (2005). Regulation of azole drugsusceptibility by Candida albicans protein kinase CK2. Molecular Microbiology. 56(2):559-573.

Calderone RA.(2001). In Fungal pathogenesis: principles and clinical applications. Edited by Calderone RA: Marcel Dekker Inc.; p 3-13.

Calderone RA, Fonzi WA. (2001). Virulence factors of Candida albicans. Trends Microbiol.

9(7):327-335. Review

Caspari T. (1997). Onset of gluconate-H+ symport in Schizosaccharomyces pombe is

regulated by the kinases Wis1 and Pka1, and requires the gti1+ gene product. J Cell Sci.

110( Pt 20):2599-2608.

Chen CG, Yang YL, Shih HI, Su CL, Lo HJ. (2004). CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob Agents Chemother. 48(12):4505-4512 Chen YC, Chang SC, Luh KT, Hsieh WC. (2003). Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother. 52(1): 71-77.

Chi Chin-Sheng (2004). 交大碩士論文.

Chu S, DeRisi J, Eisen M, Mulholland J, Botstein D, Brown PO, Herskowitz I.

(1998).The transcriptional program of sporulation in budding yeast. Science.

282(5389):699-705.

Chu S, Herskowitz I. (1998). Gametogenesis in yeast is regulated by a transcriptional cascade dependent on Ndt80. Mol Cell. 1(5):685-696.

Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. (2004). TAC1, Transcriptional activator of CDR Genes, is a new transcription factor involved in the regulation of Candida

albicans ABC transporters CDR1 and CDR2. Eukaryot Cell. 3(6):163-1652.

de Micheli M, Bille J, Schueller C, Sanglard D. (2002). A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol Microbiol. 43(5): 1197-1214.

Denning DW. (2003). Echinocandin antifungal drugs. Lancet. 362(9390):1142-1151. Review Falvo JV, Thanos D, Maniatis T. (1995). Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell.

83(7):1101-1111

Fasoli MO, Kerridge D, Morris PG, Torosantucci A. (1990) 19F nuclear magnetic resonance study of fluoropyrimidine metabolism in strains of Candida glabrata with specific defects in pyrimidine metabolism. Antimicrob Agents Chemother. 34(10):1996-2006.

Fidel PL Jr, Vazquez JA, Sobel JD. (1999) Candida glabrata: review ofepidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev.

12(1):80-96. Review

Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. (2002). Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore).

81(6):425-433.

Gaur NA, Puri N, Karnani N, Mukhopadhyay G, Goswami SK, Prasad R.

(2004) .Identification of a negative regulatory element which regulates basal transcription of a multidrug resistance gene CDR1 of Candida albicans. FEMS Yeast Research. 4(4-5):389-399.

Georgiev, V.St. (1998). Infectious Diseases in Immunocompromised Hosts, CRC Press, Boca Raton, New York.

Georgopapadakou NH. (1998). Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin.Microbiol. 1(5):547–57. Review

Georgopapadakou NH. (2001). Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Invest Drugs 10(2):269-80. Review

Gillum AM, Tsay EY, Kirsch DR. (1984). Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet. 198(1):179-82.

Girard F, Bello B, Laemmli UK, Gehring WJ. (1998). In vivo analysis of scaffold-associated regions in Drosophila: a synthetic high-affinity SAR binding protein suppresses position effect variegation. EMBO J. 17(7):2079-2085.

Hernaez ML, Gil C, Pla J, Nombela C. (1998). Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast.

14(6):517-526.

Horsburgh CR Jr, Kirkpatrick CH. (1983). Long-term therapy of chronic mucocutaneous

candidiasis with ketoconazole: experience with twenty-one patients. Am J Med. 74 (1B):23-29.

Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. (1996). Nosocomial candidemia in a university hospital in Taiwan. Journal of Formosan Medical Association 95(1):19-28.

Karnani N, Gaur NA, Jha S, Puri N, Krishnamurthy S, Goswami SK, Mukhopadhyay G, Prasad R.(2004). SRE1 and SRE2 are two specific steroid-responsive modules of Candida drug resistance gene 1 (CDR1) promoter. Yeast. 21(3):219-239.

Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, Schumacher U, Einsele H. (1997) Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta 5,6-desaturation. FEBS Lett. 400(1): 80-82.

Kohler JR, Fink GR. (1996). Candida albicans strains heterozygous and homozygous for mutations in mitogen-activated protein kinase signaling components have defects in hyphal development. Proc Natl Acad Sci USA. 93(23):13223-13228.

Krishnamurthy S, Gupta V, Prasad R, Panwar SL, Prasad R. (1998). Expression of CDR1, a multidrug resistance gene of Candida albicans: in vitro transcriptional activation by heat shock, drugs and human steroid hormones. FEMS Microbiol Lett. 160(2):191-197.

Lamb D, Kelly D, Kelly S. (1999). Molecular aspects of azole antifungal action and resistance. Drug Resist Updates. 2(6):390-402.

Lambrechts MG, Bauer FF, Marmur J, Pretorius IS. (1996). Muc1, a mucin-like protein that is regulated by Mss10, is critical for pseudohyphal differentiation in yeast. Proc Natl Acad Sci USA. 93(16): 8419-8424

Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR.(1997).

Nonfilamentous C. albicans mutants are avirulent. Cell. 90(5):939-949.

Lo HJ, Wang JS, Lin CY, Chen CG, Hsiao TY, Hsu CT, Su CL, Fann MJ, Ching YT, Yang YL. (2005). Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans. Antimicrob Agents Chemother. 49(3):1213-1215.

Lo WS, Dranginis AM. (1998). The cell surface flocculin Flo11 is required for pseudohyphae formation and invasion by Saccharomyces cerevisiae. Mol Biol Cell. 9(1):

161-171.

Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. (2002). Molecular basis of resistance to azole antifungals. Trends Mol Med. 8(2):76-81. Review

Lyons CN, White TC. (2000). Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob Agents Chemother. 44(9):2296-303.

Mazur P, Baginsky W. (1996). In vitro activity of 1,3-beta-D-glucan synthase requires the GTP-binding protein Rho1. J Biol Chem. 271(24):14604-14609.

Miller MG, Johnson AD. (2002). White-opaque switching in Candida albicans is controlled by mating-type locus homeodomain proteins and allows efficient mating. Cell.

110(3):293-302.

Murad AM, d'Enfert C, Gaillardin C, Tournu H, Tekaia F, Talibi D, Marechal D, Marchais V, Cottin J, Brown AJ. (2001). Transcript profiling in Candida albicans reveals new cellular functions for the transcriptional repressors CaTup1, CaMig1 and CaNrg1. Mol Microbiol. 42(4):981-993.

Nakamura, K., Niimi, M., Niimi, K., Holmes, A. R., Yates, J. E., Decottignies, A., Monk, B. C., Goffeau, A., Cannon, R. D. (2001). Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters.

Antimicrob Agents Chemother 45(12): 3366-3374.

Nakayama H, Mio T, Nagahashi S, Kokado M, Arisawa M, Aoki Y. (2000).

Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect Immun. 68(12):6712-6719.

Odds FC. (1988). Candida and Candidiasis edn 2. London: Bailliere Tindal

Onate SA, Prendergast P, Wagner JP, Nissen M, Reeves R, Pettijohn DE, Edwards DP.

The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. (1994). Mol Cell Biol. 14(5):3376-3391.

Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE; NIAID Mycoses Study Group. (2003). A prospective observational study of candidemia:

epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Clin Infect Dis. 37(5):634-643.

Pendrak ML, Yan SS, Roberts DD. (2004). Hemoglobin regulates expression of an activator of mating-type locus alpha genes in Candida albicans. Eukaryotic Cell. 3(3):764-775.

Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, Calabrese D, Sanglard D, Patterson TF. (2001). Prevalence of molecular mechanisms

of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Antimicrob Agents Chemother. 45(10):2676-84.

Prasad R, De Wergifosse P, Goffeau A, Balzi E. (1995). Molecular cloning andcharacterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet.27(4): 320-329.

Prasad, R., Gupta, N., Gaur, M. (2004). Molecular basis of antifungal resistance, in Pathogenic Fungi. Caister Academic Press, Norfolk, U.K. pp357-414. Caister Academic Press, Norfolk, U.K.

Prasad R, Panwar SL, Smriti. (2002). Drug resistance in yeasts--an emerging scenario.

Adv Microb Physiol. 46:155-201. Review

Puri N, Krishnamurthy S, Habib S, Hasnain SE, Goswami SK, Prasad R. (1999). CDR1,

Puri N, Krishnamurthy S, Habib S, Hasnain SE, Goswami SK, Prasad R. (1999). CDR1,